These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 26981529)

  • 1. The Role of (18)F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis.
    Liu Q; Wang C; Li P; Liu J; Huang G; Song S
    Biomed Res Int; 2016; 2016():3746232. PubMed ID: 26981529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
    Cheng X; Li Y; Liu B; Xu Z; Bao L; Wang J
    Acta Radiol; 2012 Jul; 53(6):615-27. PubMed ID: 22734080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
    Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
    Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis.
    Lin CY; Lin CL; Kao CH
    Eur J Radiol; 2018 Oct; 107():158-165. PubMed ID: 30292261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated
    Cho N; Im SA; Cheon GJ; Park IA; Lee KH; Kim TY; Kim YS; Kwon BR; Lee JM; Suh HY; Suh KJ
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):328-339. PubMed ID: 29101445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis.
    Li H; Yao L; Jin P; Hu L; Li X; Guo T; Yang K
    Breast; 2018 Aug; 40():106-115. PubMed ID: 29758503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of FDG-PET versus magnetic resonance imaging for detecting spondylitis: a systematic review and meta-analysis.
    Yin Y; Liu X; Yang X; Guo J; Wang Q; Chen L
    Spine J; 2018 Dec; 18(12):2323-2332. PubMed ID: 30121323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early prediction of pathological complete response in luminal B type neoadjuvant chemotherapy-treated breast cancer patients: comparison between interim 18F-FDG PET/CT and MRI.
    Pahk K; Kim S; Choe JG
    Nucl Med Commun; 2015 Sep; 36(9):887-91. PubMed ID: 25932536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy.
    Pengel KE; Koolen BB; Loo CE; Vogel WV; Wesseling J; Lips EH; Rutgers EJ; Valdés Olmos RA; Vrancken Peeters MJ; Rodenhuis S; Gilhuijs KG
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1515-24. PubMed ID: 24777490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis.
    Xiao Y; Wang L; Jiang X; She W; He L; Hu G
    Nucl Med Commun; 2016 Nov; 37(11):1180-8. PubMed ID: 27428888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
    Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
    Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients: comparison of diagnostic performance of ultrasound, MRI and ¹⁸F-FDG PET/CT.
    You S; Kang DK; Jung YS; An YS; Jeon GS; Kim TH
    Br J Radiol; 2015 Aug; 88(1052):20150143. PubMed ID: 26110204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The accuracy of
    Tian F; Shen G; Deng Y; Diao W; Jia Z
    Eur Radiol; 2017 Nov; 27(11):4786-4796. PubMed ID: 28477166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of magnetic resonance imaging and 18-fludeoxyglucose positron emission tomography/computed tomography in the diagnostic accuracy of staging in patients with cholangiocarcinoma: A meta-analysis.
    Huang X; Yang J; Li J; Xiong Y
    Medicine (Baltimore); 2020 Aug; 99(35):e20932. PubMed ID: 32871859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is diffusion-weighted MRI superior to FDG-PET or FDG-PET/CT in evaluating and predicting pathological response to preoperative neoadjuvant therapy in patients with rectal cancer?
    Li YL; Wu LM; Chen XX; Delproposto Z; Hu JN; Xu JR
    J Dig Dis; 2014 Oct; 15(10):525-37. PubMed ID: 25060294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer.
    Qu X; Huang X; Yan W; Wu L; Dai K
    Eur J Radiol; 2012 May; 81(5):1007-15. PubMed ID: 21354739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer.
    Park SH; Moon WK; Cho N; Chang JM; Im SA; Park IA; Kang KW; Han W; Noh DY
    Eur Radiol; 2012 Jan; 22(1):18-25. PubMed ID: 21845462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.
    Schmitz AMT; Teixeira SC; Pengel KE; Loo CE; Vogel WV; Wesseling J; Rutgers EJT; Valdés Olmos RA; Sonke GS; Rodenhuis S; Vrancken Peeters MJTFD; Gilhuijs KGA
    PLoS One; 2017; 12(5):e0176782. PubMed ID: 28531188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.